Bill118th CongressFiled Jun 6, 2023Health
H.R. 3839
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Jun 6, 2023)
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
What just happenedJun 9, 2023
Referred to the Subcommittee on Health.
Who’s behind it
Rep. Dunn, Neal P. [R-FL-2](R-FL)Sponsor
1 cosponsor1 D
1cosponsors1committees4actions4related bills4subjects
- Introduced in HouseJun 6, 2023
- Jun 9, 2023Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jun 6, 2023IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jun 6, 2023IntroReferralIntro-H
Introduced in House
- Jun 6, 2023IntroReferral1000
Introduced in House